Major booster
-Execution of Share Purchase and Shareholders’ Agreement for acquisition of 51% equity stake in Swiss Parenterals Limited at acquisition of INR 637.5 Crs. Last Year (FY2023) turnover of this company was INR 280 Cr.
-Augments the capability of Eris in the sterile injectables segment
-Country in which the acquired entity has presence: ~80+ countries
YoY Rev at 486Cr vs 423Cr
14.3%
QoQ Rev at 486Cr Vs 505Cr
3.7%
9M ended Rev: 1458Cr Vs. 1282Cr13.7%
YoY PAT at 101 Cr vs 100Cr 1%
QoQ PAT at 101Cr Vs 122Cr17.2%
9M ended PAT: 317Cr Vs. 312Cr1.5%
Q4EPS at 7.5 Rs vs 7.5 Rs Vs. 9
9M ended EPS: 23.5 Vs. 23.2
